Central retinal artery and vein occlusion as a complication of persistent hyaloid artery – a case report

Bjeloš, Mirjana; Križanović, Ana; Bušić, Mladen; Elabjer, Biljana Kuzmanović

doi:10.1186/s12886-020-01702-8

Cited by 5 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, there are at least 24 case reports of pediatric CRVO in the literature to date with patients ranging from 20 months to 18 years. Among these, neovascularization occurred in six cases, [4][5][6][7][8][9] four being diagnosed at presentation. [5][6][7][8] The longest time interval previously reported between the initial CRVO and neovascularization was 8 months in a case of a CRVO secondary to antiphospholipid syndrome.…”

Section: Discussionmentioning

confidence: 99%

“…Among these, neovascularization occurred in six cases, 4–9 four being diagnosed at presentation. 5–8 The longest time interval previously reported between the initial CRVO and neovascularization was 8 months in a case of a CRVO secondary to antiphospholipid syndrome. 9…”

Section: Discussionmentioning

confidence: 99%

“…Among these, neovascularization occurred in six cases, [4][5][6][7][8][9] four being diagnosed at presentation. [5][6][7][8] The longest time interval previously reported between the initial CRVO and neovascularization was 8 months in a case of a CRVO secondary to antiphospholipid syndrome. 9 Our report is unique in that the patient developed neovascularization 12 years after the initial insult.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Central Retinal Vein Occlusion in 12-Year-Old Girl With Methylenetetrahydrofolate Reductase Mutation: A Case Report and Review of the Literature

Hudson

Laura

Berrocal

2023

RETINAL Cases &Amp; Brief Reports

View full text Add to dashboard Cite

Purpose: This case report describes a central retinal vein occlusion in a healthy 12-year-old girl who developed retinal neovascularization at 24 years of age. To the knowledge of the authors, this is the longest time between a reported pediatric central retinal vein occlusion event and neovascularization. Methods: The patient underwent a full history, physical examination, and laboratory workup to determine potential risk factors contributing to the vascular event. Fundus photographs, optical coherence tomography, and fluorescein angiography were performed throughout the patient's treatment course. Results: Family history was noncontributory, but laboratory testing revealed a mildly elevated homocysteine level and homozygous C677T mutation in methylenetetrahydrofolate reductase. As a result, she was started on folate supplementation. The patient has had no further ocular or systemic thrombotic events to date. Conclusion: Pediatric patients presenting with central retinal vein occlusion should undergo a systemic workup and require long-term follow-up to avoid complications, such as intraocular hemorrhage, tractional retinal detachments, and neovascular glaucoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Central Retinal Vein Occlusion in 12-Year-Old Girl With Methylenetetrahydrofolate Reductase Mutation: A Case Report and Review of the Literature

Hudson

Laura

Berrocal

2023

RETINAL Cases &Amp; Brief Reports

View full text Add to dashboard Cite

show abstract

“…An appropriate diagnosis and estimation of the visual potential are essential, especially in young children, so as to determine the correct treatment for each case. Coat's Disease 11,12 Neurofibromatosis type-1 13,14 Retinoblastoma 15 Retinopathy of prematurity 8,16 Juvenile Xanthogranuloma 17 Cilliary body meduloepithelioma 18 Persistent hiperplasic primary vitreous 19 Fanconi Anemia 20 Optic nerve tumors Radiation retinopathy 15 Von Hippel Lindau Disease 18 Uveal melanoma 21 Posterior or intermediate uveitis 1 Juvenile myelomonocytic leucemia 1 Ocular metastasis 21 Systemic lupus erythematosus 22 Retinal vasoproliferative tumour 13,14 Dyskeratosis congenita 23…”

Section: Discussionmentioning

confidence: 99%

Neovascular Glaucoma in Children: A case series and a review of the literature

Nieves-Moreno

Peralta

Noval

2022

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose To study the uncommon causes and treatment options for neovascular glaucoma in children. Patients and Methods A review of the literature on neovascular glaucoma in children was conducted and we present three cases of neovascular glaucoma in children. Results We present three cases of neovascular glaucoma: two cases were secondary to a retinal vasoproliferative tumor—one to neurofibromatosis type 1 and the other to exudative retinopathy secondary to mild retinopathy of prematurity—and one case was secondary to a central retina vein occlusion secondary to an optic nerve glioma. Vision in the affected eye was severely impaired in all the children. Conclusion The diagnosis and treatment of neovascular glaucoma in children is challenging and often a complication of a systemic or late-stage ocular condition. An appropriate diagnosis and estimation of the visual potential are essential to determine the correct treatment, especially in young children.

show abstract

“…A study shows that there are about 2.5 million CRVO patients worldwide. [6] Persistent macular edema (ME) is the most important cause of visual impairment. According to the data, the incidence of ME in CRVO is 46.7%, and the low visual acuity is 57.4%.…”

Section: Introductionmentioning

confidence: 99%

Comparative efficacy and safety of antivascular endothelial growth factors for central retinal vein occlusion

Liu

Wang

et al. 2021

Medicine

View full text Add to dashboard Cite

Background: Central retinal vein occlusion (CRVO) is one of the most common retinal vascular diseases, which is closely related to systemic diseases like hypertension, diabetes and arteriosclerosis. Due of its blinding, it will seriously reduce the quality of life. Macular edema (ME) caused by CRVO is one of the serious complications of visual impairment. We found that the severity of ME in CRVO was positively associated with vascular endothelial growth factor (VEGF) in the anterior chamber. With the accelerated pace of modern life and the changed dietary structure, the incidence of this disease will continue to rise. Therefore, it is of great practical significance to seek effective treatment methods. Intraocular injection of anti-VEGF can effectively alleviate ME and improve visual acuity, showing excellent clinical application prospects. In recent years, there have been some new understandings and advances on the etiology and treatment methods of the present disease, such as the deepening into the molecular biology and gene level. Clinical studies on the efficacy of the disease have emerging. Therefore, a network meta-analysis (NMA) of anti-VEGF treatment for CRVO is particularly necessary to systematically compare its efficacy. Methods: The two reviewers will comprehensively retrieved electronic databases such as PubMed, The Cochrane Library, Wanfang database, Web of Science, Chinese Scientifific Journals Database, EMBASE, China National Knowledge Infrastructure, and China BioMedical Literature. A randomized controlled trial for CRVO against VEGF between January 2010 and June 2021 was included according to the relevant content of the study. In addition, 2 researchers will screen the literature to assess the risk bias for the included articles. We will evaluate the collected evidence and data using a Bayesian NMA method, and analyzed it with STATA and WinBUGS software. Results: Anti-VEGF is one of the effective methods for ME in CRVO patients, accordingly, this study will evaluate its efficacy and safety using a Bayesian NMA system. Conclusion: This study can provide an effective rationale for the clinical application of anti-VEGF for CRVO, contribute to the treatment of CRVO and patient condition rehabilitation in clinical work. Ethics and dissemination: Do not require. INPLASY registration number: INPLASY2021110073.

show abstract

Central retinal artery and vein occlusion as a complication of persistent hyaloid artery – a case report

Cited by 5 publications

References 19 publications

Central Retinal Vein Occlusion in 12-Year-Old Girl With Methylenetetrahydrofolate Reductase Mutation: A Case Report and Review of the Literature

Central Retinal Vein Occlusion in 12-Year-Old Girl With Methylenetetrahydrofolate Reductase Mutation: A Case Report and Review of the Literature

Neovascular Glaucoma in Children: A case series and a review of the literature

Comparative efficacy and safety of antivascular endothelial growth factors for central retinal vein occlusion

Contact Info

Product

Resources

About